Clinical Trials Logo

Manic Disorder clinical trials

View clinical trials related to Manic Disorder.

Filter by:
  • None
  • Page 1

NCT ID: NCT01734278 Completed - Manic Disorder Clinical Trials

Observational Post-Authorisation Safety Study of Asenapine (Sycrest)

OBSERVA
Start date: October 2012
Phase:
Study type: Observational

The purpose of this observational study is to evaluate the use and short term safety of Asenapine (Sycrest) in real-life usage in the Mental Health Trust Setting in the United Kingdom(UK) National Health Service (NHS). The study is to be carried out independently by the Drug Safety Research Unit (DSRU) in Southampton, although it is funded by Merck, the manufacturer of Sycrest.

NCT ID: NCT00521365 Completed - Bipolar Disorder Clinical Trials

Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.

EMMY
Start date: May 2008
Phase: Phase 4
Study type: Interventional

The primary purpose of the study is to assess the efficacy of Quetiapine extended release 600mg per day either as monotherapy or combined therapy in the treatment of patients with mania associated to Bipolar disorder. This trial will also assess the life quality and productivity loss improvement for patients from baseline to day 21.

NCT ID: NCT00431184 Completed - Bipolar Disorder Clinical Trials

Effects of Pentazocine Versus Lorazepam on Manic Symptoms

Start date: January 2007
Phase: Phase 2
Study type: Interventional

Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study. We will examine whether pentazocine, an agent with kappa-opiate activity, decreases manic symptoms.

NCT ID: NCT00422123 Completed - Mania Clinical Trials

Phase 3 /Seroquel SR Acute Mania Monotherapy - US

Start date: January 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Mania for 3 weeks. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

NCT ID: NCT00253162 Completed - Bipolar Disorders Clinical Trials

A Study of the Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol

Start date: March 2001
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) compared with placebo after 3 weeks of treatment in patients with bipolar disorder who are experiencing manic episodes. A secondary purpose of the study is to assess the maintenance of risperidone effectiveness versus haloperidol (an antipsychotic medication) after 12 weeks of treatment.

NCT ID: NCT00253149 Completed - Bipolar Disorders Clinical Trials

A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo as add-on therapy to mood stabilizers in the treatment of manic episodes associated with bipolar disorder.

NCT ID: NCT00250367 Completed - Bipolar Disorder Clinical Trials

A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder.

Start date: October 1997
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo as add-on therapy to mood stabilizers, in the treatment of manic episodes associated with bipolar disorder.